Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Quinaldine Blue. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 11/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.98 |
| ▸ | HTT | P42858 | 7/20 | 0.98 |
| ▸ | BLM | P54132 | 3/20 | 0.98 |
| ▸ | THRB | P10828 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | POLB | P06746 | 6/20 | 0.77 |
| ▸ | RAB9A | P51151 | 6/20 | 0.77 |
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.77 |
| ▸ | PKM | P14618 | 4/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.77 |
| ▸ | ALPG | P10696 | 2/20 | 0.77 |
| ▸ | RECQL | P46063 | 2/20 | 0.77 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.77 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.74 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinaldine Blue SCHEMBL466982 | 1.00 | MEN1 (0.98) | MEN1KMT2AHTTBLMTHRB | |
| Quinaldine Blue SCHEMBL30688825 | 1.00 | MEN1 (0.98) | MEN1KMT2AHTTBLMTHRB | |
| Quinaldine Blue SCHEMBL6128354 | 0.99 | MEN1 (1.00) | MEN1KMT2AHTTBLMTHRB | |
| Quinaldine Blue SCHEMBL12284820 | 0.99 | MEN1 (1.00) | MEN1KMT2AHTTBLMTHRB | |
| Quinaldine Blue SCHEMBL29837418 | 0.99 | MEN1 (1.00) | MEN1KMT2AHTTBLMTHRB | |
| Quinaldine Blue SCHEMBL5847479 | 0.99 | MEN1 (1.00) | MEN1KMT2AHTTBLMTHRB | |
| Quinaldine Blue SCHEMBL12302233 | 0.99 | MEN1 (1.00) | MEN1KMT2AHTTBLMTHRB | |
| Quinaldine Blue SCHEMBL2413213 | 0.99 | MEN1 (1.00) | MEN1KMT2AHTTBLMTHRB | |
| Quinaldine Blue SCHEMBL58012 | 0.98 | MEN1 (0.98) | MEN1KMT2AHTTBLMTHRB | |
| Quinaldine Blue SCHEMBL29431896 | 0.98 | MEN1 (0.98) | MEN1KMT2AHTTBLMTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190008848-A1 | IDENTIFICATION OF ADDITIONAL ANTI-PERSISTER ACTIVITY AGAINST BORRELIA BURGDORFERI FROM AN FDA DRUG LIBRARY | THE JOHNS HOPKINS UNIVERSITY | 2019-01-10 | — | — | US | claimed |
| CN-104560930-B | The combination target of hCBS enzyme specific inhibitors and its application | 上海交通大学 | 2018-04-03 | — | — | CN | claimed |
| CN-104546850-B | A kind of quinaldine class compound as hCBS enzyme inhibitors application | 上海交通大学 | 2017-10-17 | — | — | CN | claimed |
| WO-2017034984-A1 | IDENTIFICATION OF ADDITIONAL ANTI-PERSISTER ACTIVITY AGAINST BORRELIA BURGDORFERI FROM AN FDA DRUG LIBRARY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-03-02 | — | — | WO | claimed |
| CN-104560930-A | hCBS enzyme specific inhibitor-bonding target and application thereof | UNIV SHANGHAI JIAOTONG | 2015-04-29 | — | — | CN | claimed |
| CN-104546850-A | Application of quinaldine compound as hCBS enzyme inhibitor | UNIV SHANGHAI JIAOTONG | 2015-04-29 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2011031471-A2 | THE FUNGAL SREBP PATHWAY AS A TARGET FOR ANTI-FUNGAL AGENTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-03-17 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| CN-1738898-A | Antimicrobial activity of antibodies producing reactive oxygen species | NOVARTIS AG (CH) | 2006-02-22 | — | — | CN | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-5221590-A | Element having conductive layer in contact with acid photogenerating layer containing a dielectric binder and an onium salt photogenerator | EASTMAN KODAK COMPANY (US) | 1993-06-22 | — | — | US | claimed |